Abstract
Target specific oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban) are changing the landscape of anticoagulation. The major drawback is the absence of an effective antidote for severe bleedings and/or prior to procedures. Currently there are a few promising antidotes undergoing clinical trials. This review summarized the latest development in idarucizumab, andexanet alpha and PER977.
Highlights
Warfarin, a vitamin K antagonist (VKA), was the only oral anticoagulant for more than half a century [1]
In this review we summarized studies on antidotes to the target specific oral anticoagulants, their mechanism
A phase 3 trial has been ongoing to evaluate the reversal of the anticoagulant effects of dabigatran by idarucizumab in patients treated with dabigatran who have uncontrolled bleeding or require emergency surgeries or procedures (REVERSE AD trial) [24,25,26,27]
Summary
A vitamin K antagonist (VKA), was the only oral anticoagulant for more than half a century [1]. In 2010, dabigatran, a direct thrombin inhibitor, became the first target specific anticoagulant approved by FDA [3]. In this review we summarized studies on antidotes to the target specific oral anticoagulants, their mechanism
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
